Skip to main content

Table 2 Antidiabetic agents with dose adjustments for renal function

From: The 2021–2022 position of Brazilian Diabetes Society on diabetic kidney disease (DKD) management: an evidence-based guideline to clinical practice. Screening and treatment of hyperglycemia, arterial hypertension, and dyslipidemia in the patient with DKD

  1. *Pioglitazone, although it can be used across the entire spectrum of GFR, is associated with an increased risk of decompensated heart failure and fractures, and the potential risk–benefit should be evaluated. SU: sulfonylureas; Lim. Exp.: limited experience; GFR: Glomerular filtration rate; Source: Adapted from Escott et al. [75]